ClinConnect ClinConnect Logo
Search / Trial NCT01448655

Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)

Launched by IFAG AG · Oct 6, 2011

Trial Information

Current as of July 24, 2025

Unknown status

Keywords

Colorectal Cancer Mistletoe Supportive Treatment Long Term Study Non Interventional Cohort Study Controlled Study With Parallel Groups

ClinConnect Summary

see summary

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Confirmed diagnosis of colorectal cancer, UICC stage II-IV
  • Age between 18 (Austria: 19) and 85 years
  • No previous malign tumor
  • Surgical resection of the tumor if indicated
  • (Post-operative) conventional oncological therapy and measurements, or passive after-care ("best care")
  • Follow-up for several years feasible
  • Patient gives written consent to use the anonymized date for evaluation
  • Exclusion Criteria:
  • Anal cancer
  • Other Iscador® sorts than Qu in the test group
  • Other mistletoe preparations in the test group
  • Any mistletoe preparation in the control group
  • Non-oncological immunomodulating, -stimulating or -suppressive drugs (e.g. Echinacea, interferons, Polyerga®, BCG, azathioprine). Allowed are approved tumor inhibiting immuno- or targeted therapies (e.g. bevacizumab, cetuximab) and tumor specific vaccines
  • HIV infection, Aids, organ transplantation
  • High-dose systemic glucocorticoids
  • Contraindications for Iscador® Qu (allergy against mistletoe, acute inflammatory disease or fever \> 38.5°C, active tuberculosis, hyperthyreosis with not-adjusted metabolism, primary brain or spinal tumor, brain metastases)
  • Known mistletoe intolerance
  • Patients participating in another clinical study with non-approved substances

About Ifag Ag

Ifag AG is a leading clinical trial sponsor specializing in the development and management of innovative therapies across various therapeutic areas. With a commitment to advancing medical science, Ifag AG collaborates with research institutions and healthcare professionals to conduct rigorous clinical trials that adhere to the highest ethical and regulatory standards. The company leverages its extensive expertise and state-of-the-art technology to facilitate efficient trial execution, ensuring robust data collection and analysis. Through its dedication to improving patient outcomes, Ifag AG plays a pivotal role in bringing groundbreaking treatments from the laboratory to the market.

Locations

Vienna, , Austria

Vienna, , Austria

Bochum, , Germany

Fulda, , Germany

Halle (Saale), , Germany

Herdecke, , Germany

Munich, , Germany

Soest, , Germany

Ulm, , Germany

Patients applied

0 patients applied

Trial Officials

Thomas Seufferlein, Prof. M.D.

Principal Investigator

University Clinic Halle (Saale)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials